知镜 Cognispect · 医学文献与研究工作台

Hepatic control of immunometabolism: implications for the pathogenesis, diagnosis and treatment of rheumatic diseases.

Perl A, Banki K.
Nature reviews. Rheumatology · 2026-08-26 · PMID 42649250

文献摘要

Autoimmune rheumatic diseases, including systemic lupus erythematosus and antiphospholipid syndrome, arise from interactions between genetic susceptibility and environmental triggers that drive metabolic dysregulation. The liver, a central metabolic and immunological organ, has a key role in initiating and amplifying systemic autoimmunity and organ damage. It functions as an interface between the gut microbiome, nutrients, drugs and environmental toxins. The liver regulates immune cell development, coordinates systemic immune responses through metabolite and cytokine production and modifies self-antigens via oxidation, glycosylation and lipidation. These changes can transform normal molecules into autoantigens. Hepatocytes also produce coagulation, complement factors and apolipoproteins, such as β 2 -glycoprotein I, a major target of antiphospholipid antibodies. In addition, the liver secretes antioxidants such as glutathione, albumin and paraoxonase-1, which protect lipoproteins from becoming antigenic and reduce risks of atherosclerosis and thrombosis. Liver diseases such as steatosis and steatohepatitis have bidirectional relationships with systemic lupus erythematosus, antiphospholipid syndrome and other rheumatic conditions. Liver cells can also be direct targets of autoimmune responses. Delineating the role of the liver in metabolic control of autoimmunity and inflammation can lead to better understanding of disease pathogenesis, improved clinical diagnosis and identification of new therapeutic targets in rheumatic diseases.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。